Jan 30 (Reuters) - INNATE PHARMA SA:
* INNATE PHARMA AND MEDIMMUNE ENTER CLINICAL TRIAL COLLABORATION
* COLAB TO EVALUATE COMBINATION OF IPH5401 ANTIBODY AND IMFINZI(Â®) (DURVALUMAB) IN A PHASE I/II STUDY FOR PATIENTS WITH SELECTED SOLID TUMORS
* INNATE WILL SPONSOR STUDY WITH COSTS EQUALLY SHARED BY BOTH PARTIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 